Genentech : Longer-term Data From Studies Of Columvi & Lunsumio Show Durable Responses In Lymphomas
11/12 05:19
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), said that longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continued to show durable responses in people with heavily pre-treated lymphomas....